Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
V. Arroyo, P. Ginés, A. Gerbes, F.J. Dudley, P. Gentilini, G. Laffi, et al.
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
Hepatology, 23 (1996), pp. 164-176
[2.]
M.H. Koppel, J.N. Coburn, M.M. Mims, H. Goldtein, H. Boyle, M.E. Rubini.
Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease.
N Engl J Med, 280 (1969), pp. 1367-1371
[3.]
S. Iwatsuki, M.M. Popovtzer, J.L. Corman, M. Ishikawa, C.W. Putnam, F.H. Katz, et al.
Recovery from hepatorenal syndrome after orthotopic liver transplantation.
N Engl J Med, 289 (1973), pp. 1155-1159
[4.]
R.W. Schrier, V. Arroyo, M. Bernardi, M. Epstein, J.H. Henriksen, J. Rodés.
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
Hepatology, 8 (1988), pp. 1151-1157
[5.]
A. Ginès, A. Escorsell, P. Ginès, G. Fernández-Esparrach, J. Salo, W. Jiménez, et al.
Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites.
Gastroenterology, 105 (1993), pp. 229-236
[6.]
M. Guevara, P. Gines, G. Fernández-Esparrach, P. Sort, J.M. Salmeron, W. Jiménez, et al.
Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Hepatology, 27 (1998), pp. 35-41
[7.]
V. Gülberg, M. Bilzer, A.L. Gerbes.
Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Hepatology, 30 (1999), pp. 870-875
[8.]
O. Le Moine, A. el Nawar, R. Jagodzinski, N. Bourgeois, M. Adler, M. Gelin, et al.
Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome.
Acta Gastroenterol Belg, 61 (1998), pp. 268-270
[9.]
N. Ganne-Carrie, A. Hadengue, P. Mathurin, F. Durand, S. Erlinger, J.P. Benhamou.
Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
Dig Dis Sci, 41 (1996), pp. 1054-1056
[10.]
J. Uriz, P. Ginés, A. Cardenas, P. Sort, W. Jiménez, J.M. Salmerón, et al.
Terlipressin plus albumin infusion is an effective and safe therapy of hepatorenal syndrome.
J Hepatol, 33 (2000), pp. 43-48
[11.]
J.P. Mulkay, H. Louis, V. Donckter, N. Bourgeois, M. Adler, J. Deviere, et al.
Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
Acta Gastroenterol Belg, 64 (2001), pp. 15-19
[12.]
R. Ortega, P. Ginès, J. Uriz, A. Cardenas, B. Calahorra, D. de las Heras, et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome. Results of a prospective, non-randomized study.
Hepatology, 36 (2002), pp. 941-948
[13.]
R. Moreau, F. Durand, T. Poynard, C. Duhamel, J.P. Cervoni, P. Ichai, et al.
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a restrospective multicenter study.
Gastroenterology, 50 (2002), pp. 90-94
[14.]
P. Angeli, R. Volpin, G. Gerunda, R. Craighero, P. Romero, R. Merenda, et al.
Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Hepatology, 29 (1999), pp. 1690-1697
[15.]
C. Duvoux, D. Zanditenas, C. Hezode, A. Chauvat, J. Metreau.
Noradrenalin for treatment of type 1 hepatorenal syndrome (HRS).
J Hepatol, 34 (2001), pp. 103A
[16.]
M. Guevara, P. Ginés, J.C. Bandi, R. Gilabert, P. Sort, W. Jiménez, et al.
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Hepatology, 28 (1998), pp. 416-422
[17.]
K.A. Brensing, J. Textro, J. Perz, P. Schiedermaier, P. Raab, H. Strunk, et al.
Long-term outcome after transjugular intrahepatic portosystemic stent-shunt in non-trasplant patients with hepatorenal syndro-me: a phase II study.
Gut, 47 (2000), pp. 288-295
[18.]
A. Ochs, M. Rössle, K. Haag, A. Gerbes, A. Morgenroth, P. Deibert, et al.
TIPS for hepatorenal syndrome.
Hepatology, 20 (1994), pp. 114A
[19.]
I. Alam, N.M. Bass, J.M. LaBerge, E. Ring, K.A. Somberg.
Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS).
Gastroenterology, 108 (1995), pp. A1024
[20.]
P. Ginès, J. Uriz, B. Calahorra, G. García-Tsao, P.S. Kamath, L.R. Del Árbol, et al.
Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis.
A multicenter randomised comparative study Gastroenterology, 123 (2002), pp. 1839-1847
[21.]
S.L. Linas, J.W. Shaffer, E.E. Moore, J.T. Good Jr, R. Giansiracusa.
Peritoneovenous shunt in the management of the hepatorenal syndrome.
Kidney Int, 30 (1986), pp. 736-740
[22.]
P. Ginés, V. Arroyo, V. Vargas, R. Planas, F. Casafont, J. Panés, et al.
Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites.
N Engl J Med, 325 (1991), pp. 829-835
[23.]
G.O. Pérez, T.A. Golper, M. Epstein, J.R. Oster.
Dyalisis hemofiltration, and other extracorporeal techniques in the treatment of renal complications of liver disease.
The Kidney in liver disease, 4th ed, pp. 517-528
[24.]
S.R. Mitzner, J. Stange, S. Klammt, T. Risler, C.M. Erley, B.D. Bader, et al.
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized controlled clinical trial.
Liver Transpl, 6 (2000), pp. 277-286
[25.]
T.A. Gonwa, C.A. Morris, R.M. Goldstein, B.S. Husbert, G.B. Klintmalm.
Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndromeexperience in 300 patients.
Transplantation, 91 (1991), pp. 428-430
[26.]
M. Navasa, F. Feu, J.C. García-Pagan, W. Jiménez, J. Llach, A. Rimola, et al.
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis.
Hepatology, 17 (1993), pp. 355-360
[27.]
P. Ginés, L. Tito, V. Arroyo, R. Planas, J. Panes, J. Viver, et al.
Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
Gastroenterology, 94 (1988), pp. 1493-1502
[28.]
P. Sort, M. Navasa, V. Arroyo, X. Aldeguer, R. Planas, L. Ruiz del Árbol, et al.
Effect of plasma volume expansion on renal impaiment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.
N Engl J Med, 341 (1999), pp. 403-409
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
